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Abstract
Radionuclide bone metastases therapy is a major achievement
of nuclear medicine. Development of less radiotoxic and more
effective radiopharmaceuticals is therefore a challenge for ra-
diopharmacists and industry. This paper reviews the applica-
tion of rhenium-188 HEDP as a reactor- or generator-produced
nuclide for bone metastases therapy.
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Introduction
Bone metastases might occur in most of neoplasmatic dis-
eases. Breast, prostate, lung and renal cancer are the most com-
mon cancers with skeletal spread. 70% of those patients suffer
from bone pain [1]. Patients with bone metastases have longer
survival than patients with extraosseous neoplasmatic dissemi-
nation [2]. Radionuclide therapy in painful bone metastases was
introduced in the early 40 s [3, 4]. Today strontium-89, samarium-
153 EDTMP and rhenium-186 HEDP are  the most popular ra-
diopharmaceuticals in treatment of patients with widespread skel-
etal metastases. Several other radiopharmaceuticals are current-
ly introduced. One of them is rhenium-188
Rhenium-188 properties
Rhenium-188 is a relative new and attractive therapeutic ra-
dioisotope. It emits high-energy  b– radiation with mean energy of
0.76 MeV, maximal — 2.1 MeV and g rays with energy of 155 keV.
Gamma-radiation enables in vivo pharmacokinetic studies and
dosimetric calculations [5]. A physical half-life of rhenium-188 is
16.9 hours [6].
Rhenium-188 can be produced in two ways: in the reactor or in
the generator. In the reactor it is produced by neutron irradiation of
enriched rhenium-187 [7, 8]. The more common method is using
a tungsten-188/rhenium-188 generator [7] similar to molibden-99/
/technetium-99m, as rhenium-188 is a chemical analog to techne-
tium-99m [8]. Tungsten-188 parent nuclide is available in a relative-
ly low specific activity (< 0.15–0.19 GBq/mg; < 4–5 mCi/mg) from
reactor irradiation of enriched tungsten-186 [9]. The rhenium-188
daughter nuclide is obtained as sodium perrhenate by elution of
alumina-based tungsten-188/rhenium-188 generator with 0.9%
saline. Relatively large volumes of 0.9% saline (> 15 ml) are re-
quired for elution so solutions are of relatively low specific activity
concentration of rhenium-188 (< 1 GBq/ml for the 18.5 GBq gen-
erator) [9].
Therefore, this eluate needs concentration. Using tandem ion-
exchange columns it is possible to concentrate rhenium-188 saline
solution in active concentration of  18.5 GBq/ml (500 mCi/ml) [7].
Ammonium acetate (0.3 mole/L) is also proposed to use for gener-
ator elutions with similar results. After passage through a tandem
cation-anion column system eluate of low volume (< 1 mL) of sa-
line shows activity 11.1–14.8 GBq rhenium-188 (300–400 mCi) [9].
The generator can be used for 3 months to one year with no de-
crease in performance [7, 9]. Therefore rhenium-188 can be obtained
easily at reasonable costs for routine preparation for treatment.
Rhenium-188 HEDP biodistribution
 b– emitters are usually labelled with diphosphonates for thera-
peutic application. Hsieh et al. in their study compared labelling
methylene diphosphonate (MDP), hydroxymethane diphosphonate
(HDP) and hydroxyethylidene diphosphonate (HEDP) with rheni-
um-188 [10]. They analysed the biodistributions and bone uptakes
of these radiopharmaceuticals (four hours after intravenous injec-
tion of approximately 0.037 GBq (1 mCi) rhenium-188-labelled
diphosphonate) in rabbits. Rhenium-188 HEDP demonstrated to
be the best choice among these three bone-seeking drugs [10].
Rhenium-188 HEDP complex shows stability in vitro and in
vivo [11, 12]. Rhenium-188 HEDP proves to have high bone affin-
ity and high bone lesion uptake. The bone to soft tissue ratio is
25.06 [10], uptake in bone metastases us similar to technetium-
99m bone-seeking agents [13]. The lesion/normal bone uptake
ratio was 4.23 ± 0.21 in rabbits injected with rhenium-188 HEDP
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in comparison in those injected with technetium-99m MDP
(4.25 ± 0.23) [6].
The biological half-life in bone is long (60.86 h). In compari-
son, the biological half-life in muscle and blood are short: 2.99 h
and 6.21 h respectively [6].
Lin et al. in their study analysed the biodistribution following
intravenous injection of rhenium-188 HEDP (0.014 Bq; 0.4 mCi) in
rats [6]. They measured the radioactivity in the lung, liver, muscle,
spleen, testes, blood, stool and values were all lower than
0.3 percent of injected dose per gram or per ml at 1 h post injection.
Most of the radiotracer is excreted with urine [6]. 25–32% of
the administered radiopharmaceutical is eliminated via the urinary
tract in the first three hours post injection, 70% of injected radiop-
harmaceutical is found in urine in over six hours [14].
Rhenium-188 HEDP external dosimetry
Three hours after rhenium-188 HEDP (3 GBq; 80 mCi) admin-
istration at 1 meter from the anterior mid-trunk of the patient gam-
ma radiation dose rate values were 6.3 ± 1.0 microSv/h for gam-
ma, and of 183 ± 40 microSv/h for beta-radiation were found [15].
This enables the same-day, outpatient therapy of disseminat-
ed skeletal metastases with rhenium-188 HEDP [8].
Rhenium-188 HEDP efficacy
of bone pain palliation
Analysing the efficiency in pain palliation of bone metastases
of diverse radioagents Liepe et al. compared therapeutic course
utilising rhenium-188 HEDP (2.943 ± 0.609 GBq), rhenium-186
HEDP (1.341 ± 0.161 GBq) and strontium-89 (0.152 ± 0.018 GBq).
81% of patients after rhenium-188 HEDP, 77% after rhenium-186
HEDP and 80% after strontium-89 reported relief of pain. The Kar-
nofsky-Index established by patients seems to be a little higher in
group treated with rhenium-188 HEDP however this value was
only statistically significant (p = 0.001) [16]. Comparable outcomes
were achieved by Li and colleagues [17]. In this clinical trial mean
administrated dose of rhenium-188 HEDP was 1.1 GBq (31 mCi),
moreover 23 patients received repeated treatments, with a total
dose ranging from 2.3 GBq (63 mCi) to 6.9 GBq (188 mCi) result-
ing in a higher response. Relief of pain occurred in 49 of 61 pa-
tients (80%), with a complete response in 22 (36%) patients and
with a significant response in 27 (44%) patients. In 12 (20%) cas-
es, response was not apparent. In 38 patients treated with a sin-
gle dose, 8 (21%) patients had complete pain relief, 21 (55%)
patients showed significant response, and 9 (24%) patients had
no response [17].
Less positive response rate was reported by Palmedo et al.
with overall response 64% of patient with relief in bone pain. In this
study patients received single injection of escalating doses of rhe-
nium-188 HEDP [1.3 GBq (35 mCi), 2.6 GBq (70 mCi), 3.3 GBq
(90 mCi) and 4.4 GBq (120 mCi)]. The response rate seemed to
increase with higher doses, reaching 75% in the 4.4 GBq group [18].
Analgesic drug intake was studied in twenty-one patients with
different cancers who were received 1.3 GBq (35 mCi) or 2.2 GBq
(60 mCi) of rhenium-188 HEDP in single and multiple doses.
A decrease of 62% in analgesic drug treatment was reported for
78% of treated patients. Opiates were used in 78% of patients
before radionuclide therapy and as a result of therapy 58%
of patients abandoned drug intake at rest [14].
The duration of pain relief lasts from 1 to 3 months and 4.9%
of patients showed a long-term effect lasting 4 to 6 months. Re-
bound pain (“flare phenomena”) occurred in 6.5% of patients. Most
of them experienced pain relief 1 week later [17].
PSA level in 23 prostate carcinoma patients with bone metastas-
es was documented during rhenium-188 HEDP therapy for assess-
ment of tumoricidal effect. After therapy 22% of those patients pre-
sented decrease in tumour marker level for several months [19].
Li et al. reported a case of patient with breast cancer and bone
metastases proven in computed tomographic and whole-body
bone scans, with heavy bone pain that did not respond to large
doses of analgesics. Two weeks after a single dose of 1.11 GBq
(30 mCi) rhenium-188 HEDP administration, she experienced com-
plete relief of pain and remained pain free for 5 months. On bone
scan follow-up approximately one half of the metastatic foci dis-
appeared especially in the ribs, spine and pelvic bones [17].
Myelotoxicity and side-effects
Rhenium-188 is a radionuclide with a very high radiaton ener-
gy; therefore the  myelotoxicity is a limiting factor in the treatment.
Thrombocyto- and leukopenia are the most important side-effects
[18] as platelets and white blood cells are being most sensitive to
the effects of radiation [15]. However, short tissue range and short
half-life result in the relative sparing of the bone marrow while de-
livering a high radiation dose to the bone metatases [5] and in
fact no significant haematological toxicity was documented.
The maximum tolerated dose of rhenium-188 HEDP in pros-
tate cancer patients with osseous metastases was assessed by
Palmedo et al. [18]. Patients received a single injection of escalat-
ing doses of rhenium-188 HEDP [1.3 GBq (35 mCi), 2.6 GBq
(70 mCi), 3.3 GBq (90 mCi) and 4.4 GBq (120 mCi)]. In the
1.3 GBq group, no hematological toxicity was observed. The most
unfavourable results were achieved in the 4.4 GBq dose group: throm-
bocytopenia of grades 3 and 4 was observed respectively in one
and in two patients (baseline thrombocyte count < 200 × 10 (9)/L),
leukopenia of grade 3 was showed in one patient. In patients with
thrombocyte counts above 200 × 10 (9)/L, a dose of 4.4 GBq
might be tolerable [18].
Liepe et al. compared level of thrombocytes before and after
administration of rhenium-188 HEDP, rhenium-186 HEDP and stron-
tium-89 in bone metastases breast and prostate carcinoma pa-
tients. In the result there was no significant difference in the bone
marrow impairment between those various radionuclides [16].
The nadir of thrombocytopenia and leukopenia in majority of
cases was noted at forth week and returned to baseline level with-
in 8 weeks [16].
Adverse side-effects including low-grade fever, nausea, vom-
iting and arthrodynia of the knees might appeared after rhenium-
188 HEDP injection. All of which resolved spontaneously within 1
or 2 days. Li et al. observed those symptoms at 16.4% of treated
patents [17].
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Conclusions
Nowadays systemic radionuclide therapy is consider as ef-
fective, safe, feasible, well tolerated and cost- effective method of
treatment of bone metastases. Radiopharmacotherapy is shifting
towards radioisotopes with short tissue range and short half-de-
cay time to prevent bone marrow lesion. An administration of low
doses of activity (3 GBq; 80 mCi) deliver high beta-energy radia-
tion to metastasis focus and can bring about a pain reduction
without causing any clinically significant bone marrow toxicity [14].
Due to rhenium-188 HEDP physical and biological properties
it could be a beneficial radionuclide for repeated application with
small activity (30 mCi) used in similar manner like samarium-153
in Vienna protocol.
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